Related Experiment Video
Updated: Jun 21, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma
Amanda Braga Figueiredo1,2,3, Milton José Barros E Silva4, Guilherme Ferreira de Britto Evangelista1
1Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Abstract:
The treatment for stage III melanoma has advanced significantly, nevertheless, a substantial proportion of patients experience relapse. Neoadjuvant immune checkpoint blockade has emerged as a promising approach, allowing early micrometastatic disease treatment, reduction of tumor burden before surgery, and enhanced tumor-specific T-cell responses. However, not all patients respond to treatment, highlighting the need for understanding immune mechanisms behind failure and identification of predictive markers. Here we performed a robust evaluation of systemic and tumoral immune profiles in a well-defined cohort of advanced melanoma patients treated with immune checkpoint inhibitors. Elevated CTACK and CXCL9 chemokines pre-treatment suggested their potential as predictive tools for treatment response. Furthermore, CD95 expression in CD8+ T lymphocytes surfaced as a favorable prognostic indicator, while PD-1, CD161, and PD-L2 exhibited correlations with worst outcomes. These findings shed light on the intricate interplay between immune markers and melanoma response to neoadjuvant immune checkpoint therapy, offering insights into personalized treatment strategies.
Insights
Neoadjuvant immune checkpoint blockade shows promise for advanced melanoma, but not all patients respond. Researchers identified immune markers like CTACK, CXCL9, CD95, PD-1, CD161, and PD-L2 that predict treatment success or failure.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Stage III melanoma treatment has improved, yet relapse remains common.
- Neoadjuvant immune checkpoint blockade offers early treatment and enhanced immune response.
- Predictive markers are needed to identify non-responders and optimize therapy.
Purpose of the Study:
- To evaluate systemic and tumoral immune profiles in advanced melanoma patients receiving neoadjuvant immune checkpoint inhibitors.
- To identify immune markers that predict response to neoadjuvant immunotherapy.
- To understand immune mechanisms underlying treatment failure.
Main Methods:
- Analysis of systemic and tumoral immune profiles in a cohort of advanced melanoma patients.
- Assessment of chemokine levels (CTACK, CXCL9) pre-treatment.
- Evaluation of immune cell markers (CD95, PD-1, CD161, PD-L2) on CD8+ T lymphocytes.
Main Results:
- Elevated pre-treatment CTACK and CXCL9 levels correlated with treatment response.
- Higher CD95 expression on CD8+ T cells indicated a favorable prognosis.
- Increased PD-1, CD161, and PD-L2 expression were associated with poorer outcomes.
Conclusions:
- CTACK and CXCL9 show potential as predictive biomarkers for neoadjuvant immunotherapy in melanoma.
- CD95, PD-1, CD161, and PD-L2 expression levels can inform prognostic assessment.
- These findings contribute to understanding immune responses and developing personalized treatment strategies for advanced melanoma.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...